ATAI News and Press, ATAI Life Sciences N.V. From 05/23/24

2024-05-23 12:15:00 ET Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi disc...

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunste...

A few months from now, the U.S. Food and Drug Administration (FDA) will be deciding whether MDMA can be prescribed as a treatment for post-traumatic stress disorder (PTSD”. MDMA, which is commonly known as ecstasy, is currently classified as a Schedule I drug under the Controlled Subst...

2024-05-15 12:54:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ATAI Life Sciences (NASDAQ: ATAI ) just reported results for the first quarter of 2024. ATAI Life Sciences reported earnings per share of -17 cents. This was above the ana...

2024-05-15 07:56:35 ET More on ATAI Life Sciences Psychedelic drug developers could benefit from NIH funding for chronic pain Atai Life Sciences upgraded at Maxim on Beckley investment Seeking Alpha’s Quant Rating on ATAI Life Sciences Historical earni...

First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b to...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

American researchers will be able to study various psychedelics and their effects on the human body much more effectively if hallucinogens are finally deregulated after decades of state and federal prohibition. Similar to how cannabis research opened up after dozens of states legalized either r...

2024-05-07 05:54:17 ET More on psychedelic therapies MindMed: Breakthrough Status From FDA For LSD Therapy COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way? Mind Medicine: GAD Program Success Continues With BTD MindMed releases promising data on LSD-...

2024-04-29 13:37:07 ET More on psychedelic drug developers Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin spikes after FDA breakthrough tag for psychedelic therapy Psychedelic stocks gain after FDA priority review for MDMA therapy ...